Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.

Jansen GH, Franke HR, Wolbers F, Brinkhuis M, Vermes I.

Climacteric. 2008 Aug;11(4):315-21. doi: 10.1080/13697130802232500.

PMID:
18645697
2.

Apoptosis and proliferation in breast cancer cells, cultured in vitro: effects of SERMs.

Werner HM, Franke HR, Vermes I.

Climacteric. 2005 Sep;8(3):294-9.

PMID:
16390761
3.

Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.

Vanderlaag KE, Hudak S, Bald L, Fayadat-Dilman L, Sathe M, Grein J, Janatpour MJ.

Breast Cancer Res. 2010;12(3):R32. doi: 10.1186/bcr2586. Epub 2010 Jun 4.

4.

The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.

Ikeda H, Taira N, Hara F, Fujita T, Yamamoto H, Soh J, Toyooka S, Nogami T, Shien T, Doihara H, Miyoshi S.

Breast Cancer Res. 2010;12(3):R43. doi: 10.1186/bcr2598. Epub 2010 Jun 28.

5.

Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.

Hutcheson IR, Goddard L, Barrow D, McClelland RA, Francies HE, Knowlden JM, Nicholson RI, Gee JM.

Breast Cancer Res. 2011 Mar 11;13(2):R29. doi: 10.1186/bcr2848.

6.

In vitro effects of estradiol, dydrogesterone, tamoxifen and cyclophosphamide on proliferation vs. death in human breast cancer cells.

Franke HR, Kole S, Ciftci Z, Haanen C, Vermes I.

Cancer Lett. 2003 Feb 10;190(1):113-8.

PMID:
12536084
7.

Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.

Ikeda H, Taira N, Nogami T, Shien K, Okada M, Shien T, Doihara H, Miyoshi S.

Cancer Sci. 2011 Nov;102(11):2038-42. doi: 10.1111/j.1349-7006.2011.02050.x. Epub 2011 Sep 1.

8.

Dehydroepiandrosterone sulfate causes proliferation of estrogen receptor-positive breast cancer cells despite treatment with fulvestrant.

Calhoun KE, Pommier RF, Muller P, Fletcher WS, Toth-Fejel S.

Arch Surg. 2003 Aug;138(8):879-83.

PMID:
12912747
9.

Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.

Sui M, Jiang D, Hinsch C, Fan W.

Breast Cancer Res Treat. 2010 Jun;121(2):335-45. doi: 10.1007/s10549-009-0472-4. Epub 2009 Jul 22.

PMID:
19626437
11.

Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.

Planas-Silva MD, Waltz PK, Kilker RL.

J Steroid Biochem Mol Biol. 2006 Mar;98(4-5):193-8. Epub 2006 Feb 7.

PMID:
16464573
12.

Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.

Pasqualini JR, Chetrite GS.

J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):221-36. Review.

PMID:
15860265
13.

Effects of estradiol, progestogens, and of tibolone on breast proliferation and apoptosis.

Pompei LM, Cunha EP, Steiner ML, Theodoro TR, Mader AM, Petri G, Pinhal MA, Fernandes CE.

Climacteric. 2015;18(4):518-22. doi: 10.3109/13697137.2015.1020482. Epub 2015 Apr 1.

PMID:
25830529
16.
17.

Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.

Chang J, Sui M, Fan W.

Breast Cancer Res Treat. 2012 Aug;134(3):969-80. doi: 10.1007/s10549-012-1994-8. Epub 2012 Feb 29.

PMID:
22374518
18.

Classification of breast cancer cells on the basis of a functional assay for estrogen receptor.

Biswas DK, Averboukh L, Sheng S, Martin K, Ewaniuk DS, Jawde TF, Wang F, Pardee AB.

Mol Med. 1998 Jul;4(7):454-67.

19.

Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway.

Saussede-Aim J, Matera EL, Ferlini C, Dumontet C.

Cell Motil Cytoskeleton. 2009 Jul;66(7):378-88. doi: 10.1002/cm.20377.

PMID:
19466750
20.

Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.

Oakman C, Moretti E, Santarpia L, Di Leo A.

Future Oncol. 2011 Feb;7(2):173-86. doi: 10.2217/fon.10.179. Erratum in: Future Oncol. 2011 Jun;7(6):802-6.

PMID:
21345137

Supplemental Content

Support Center